GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-06-28| Trials & Approvals

Lilly’s Oral GLP-1 Agonist Shows Encouraging Results for Weight Management

by GeneOnline
Share To

The pharmaceutical company, Eli Lilly and Company announced new data for their phase 2 diabetes and obesity medicine, Orforglipron. The data was presented at the American Diabetes Association’s 83rd Scientific Sessions and published in the New England Journal of Medicine. It showed that the drug met primary and secondary efficacy endpoints, as well as up to 14.7% mean weight reduction in obese or overweight adults at 36 weeks. 

Related Article: Pfizer Begins Phase 2 Of Diabetes Drug, Triggering $10 Million Milestone To Sosei Heptares

New Treatment options for Diabetes and Obesity with Oral Medication 

On June 23, Lilly presented new data for their diabetes and obesity pipeline. Their phase 2 trials of their medication, Orforglipron, for the treatment of type 2 diabetes and obesity show promising results. They have stated that they intend to initiate a phase 3 development program for the medication.  This will help further examine how effective and safe it is at treating type 2 diabetes and obesity. 

Orforglipron is a glucagon-like peptide-1 (GLP-1) receptor agonist being developed for the treatment of diabetes and obesity. GLP-1 agonists are a class of medications that are normally injected daily or weekly. They are used for the treatment of diabetes type 2 and obesity. This is Lilly’s first once-daily oral medication in development, but more importantly, it represents a promising alternative to the existing administration routes. 

Phase 2 Trials of Orforglipron Show Promise 

Lilly’s phase 2 trial of the medication tested the efficacy and safety of four different doses (12, 24, 26, and 45 mg) of Orforglipron in obese or overweight adults. The participants percentage body weight change was evaluated at the primary (26 weeks) and secondary (36 weeks) endpoints. At week 26, the weight reductions mean change ranged from 8.6% to 12.7%. The weight reduction trend continued at 36 weeks, with a mean change in weight reduction of 9.4% to 14.7%. The results from their phase 2 data show that Orforglipron is associated with weight reduction, and its safety profile is similar to that of injectable GLP-1 agonists. The most common adverse events reported in the trial were mild to moderate gastrointestinal side effects that were observed during the dose escalation of the medication. 

Additionally, a phase 2 study for the same medication in patients with type 2 diabetes was published by Lilly in The Lancet. It demonstrated that Orforglipron attained substantial decreases in HbA1c and bodyweight. This data highlights orforgliporn’s potential as a once-daily oral treatment for people suffering from type 2 diabetes and obesity. It could potentially offer an alternative to the existing injectable GLP-1 agonist medications.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
Lilly’s Omvoh’s Two-Year Journey Confirms Lasting Impact on Crohn’s Disease Treatment
2025-02-08
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top